文献速递间质性肺疾病

硫唑嘌呤与霉酚酸酯长期治疗肌炎相关间质性肺疾病

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
PubMed 文献 · Chest · 2019-06-22

两组FVC%预计值均改善且泼尼松剂量减少,AZA组Dlco%预计值亦改善;校正后两组FVC%和Dlco%无显著差异,但AZA组36个月时泼尼松剂量低6.6 mg。AZA不良事件更常见(33.3% vs 13.6%,P=.04)。

要点

  • AZA和MMF治疗M-ILD均与FVC%预计值改善及泼尼松减量相关。
  • AZA组Dlco%预计值改善,MMF组未报告Dlco改善。
  • 36个月时AZA组泼尼松剂量较MMF组低6.6 mg。

核心结论

  • 在M-ILD中,AZA治疗与FVC%预计值和Dlco%预计值改善及更低泼尼松剂量相关。
  • MMF治疗与FVC%预计值改善及泼尼松剂量降低相关。
  • 36个月后AZA组泼尼松剂量低于MMF组。

研究设计与样本

  • 仅纳入使用AZA或MMF且无其他保类固醇药物的患者。
  • 采用线性混合效应模型校正性别、年龄、抗合成酶抗体和吸烟状态。

主要发现

  • 治疗开始时AZA组平均FVC%预计值和Dlco%预计值显著低于MMF组。
  • 两组FVC%预计值在2至5年内均改善且泼尼松剂量减少。
  • 仅AZA组Dlco%预计值改善。
  • 校正模型显示两组治疗后FVC%预计值平均差异1.9、Dlco%预计值平均差异-8.2,均无显著差异。
  • AZA组36个月时泼尼松剂量较MMF组低6.6 mg。

临床怎么用

  • AZA和MMF均可作为M-ILD的长期保类固醇治疗选择。
  • 选择AZA时需关注其较高的不良事件风险。
  • AZA可能有助于在长期治疗中进一步降低泼尼松剂量。

局限性

  • 回顾性研究设计。
  • 治疗开始时AZA组肺功能显著低于MMF组,可能存在基线差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of azathioprine (AZA) and mycophenolate mofetil (MMF) for interstitial lung disease (ILD) has been described, but mainly in connective tissue disease-associated ILD. The objective of this study was to evaluate the effect of AZA and MMF on lung function and prednisone dose in myositis-related ILD (M-ILD). METHODS: In this retrospective study, patients with M-ILD seen at Johns Hopkins and treated with AZA or MMF and no other steroid-sparing agents were included. Linear mixed-effects models adjusted for sex, age, antisynthetase antibody, and smoking status were used to compare the change in FVC % predicted, diffusing capacity of the lungs for carbon monoxide (Dlco) % predicted, and prednisone dose. RESULTS: Sixty-six patients with M-ILD were treated with AZA and 44 with MMF. At treatment initiation, mean FVC % predicted and Dlco % predicted were significantly lower in the AZA group than in the MMF group. In both groups, FVC % predicted improved and the prednisone dose was reduced over 2 to 5 years; however, for Dlco % predicted, only the AZA group improved. The adjusted model showed no significant difference in posttreatment FVC % predicted or Dlco % predicted between groups (mean difference of 1.9 and -8.2, respectively), but a 6.6-mg lower dose of prednisone at 36 months in the AZA group. Adverse events were more frequent with AZA than MMF (33.3% vs 13.6%; P = .04). CONCLUSIONS: In M-ILD, AZA treatment was associated with improved FVC % predicted and Dlco % predicted, and lower prednisone dose. Patients treated with MMF had improved FVC % predicted and lower prednisone dose. After 36 months, patients treated with AZA received a lower prednisone dose than those treated with MMF.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest. 2019. PMID: 31238042. doi:10.1016/j.chest.2019.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。